 NantKwest, Inc. Nasdaq: NK, a next-generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer NK cells to treat cancer and infectious diseases, today announced dosing of the first patient in a Phase 2 trial for second- and third-line Merkel cell carcinoma MCC in patients who are refractory to immune checkpoint inhibitors. The trial will evaluate the Companys first-in-class, off-the-shelf CD16-targeted natural killer haNK cells in combination with ImmunityBios IL-15 superagonist N-803 and Avelumab. 